“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.

Cameron Gofton

Yadhavan Upendran

Ming-Hua Zheng

Jacob George

Clinical and Molecular Hepatology

CLINICAL AND MOLECULAR HEPATOLOGY (CLIN MOL HEPATOL) 是一本国际性的、同行评审的、开放获取的期刊，每季度以英文出版。 CLIN MOL HEPATOL 旨在分享肝胆疾病的先进和最新知识、趋势和理解，为临床医生、转化研究人员和基础科学家之间的积极辩论和讨论提供一个广泛开放的学术论坛，并通过多学科合作改善公共卫生方法，特别是在资源有限的亚太地区，B 病毒感染和肝细胞癌的高发地区。此外，CLIN MOL HEPATOL 重点开展东亚、北亚、东南亚、中亚、南亚、西南亚、太平洋、非洲、中欧、东欧、中美洲和南美洲的肝胆疾病流行病学研究。

Clinical and Molecular Hepatology (CLIN MOL HEPATOL) is an international, peer-reviewed, open-access journal published quarterly in English. The journal aims to share advanced and up-to-date knowledge, trends, and understanding of hepatobiliary diseases, providing a broad academic forum for active debate and discussion among clinicians, translational researchers, and basic scientists. It seeks to improve public health approaches, particularly in resource-limited regions of the Asia-Pacific, where there is a high prevalence of hepatitis B virus infection and hepatocellular carcinoma. Furthermore, CLIN MOL HEPATOL focuses on epidemiological studies of hepatobiliary diseases in East Asia, North Asia, Southeast Asia, Central Asia, South Asia, Southwest Asia, the Pacific, Africa, Central Europe, Eastern Europe, Central America, and South America.

《Clinical and Molecular Hepatology》（CLIN MOL HEPATOL）是一本国际同行评审的开放获取期刊，每季度以英文出版。该期刊旨在分享肝胆疾病的最新研究成果和发展趋势，为临床医生、转化研究人员和基础科学家提供一个广泛的学术论坛，以促进积极的讨论和交流。期刊特别关注在资源有限的亚太地区，尤其是B型肝炎病毒感染和肝细胞癌高发地区的公共卫生改善。此外，《Clinical and Molecular Hepatology》还重点开展东亚、北亚、东南亚、中亚、南亚、西南亚、太平洋、非洲、中欧、东欧、中美洲和南美洲的肝胆疾病流行病学研究。

Clin Mol Hepatol

MAFLD: How is it different from NAFLD?

The current article explores the differences betweenMAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.

Category	Quartile
医学	1
医学, 胃肠肝病学	2

MAFLD: How is it different from NAFLD?

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info